I
Immatics N.V. (IMTX)
NCM – Real Time Price. Currency in USD
11.39
-0.15 (-1.30%)
At close: May 12, 2026, 4:00 PM EDT
11.39
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
11.39
-0.15 (-1.30%)
At close: May 12, 2026, 4:00 PM EDT
11.39
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
| Name | Position |
|---|---|
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer |
| Mr. Edward A. Sturchio | General Counsel & Secretary |
| Mr. Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting & Accounting |
| Mr. Steffen Walter Ph.D. | Chief Operations Officer |
| Ms. Amie Krause | Chief People Officer |
| Ms. Lauren Schroeder | Vice President of Marketing |
| Date | Type | Document |
|---|---|---|
| 2026-04-21 | 6-K | dp245406_6k.htm |
| 2026-04-17 | 6-K | dp245235_6k.htm |
| 2026-03-05 | 20-F | imtx-20251231.htm |
| 2026-01-12 | 6-K | dp239791_6k.htm |
| 2025-12-11 | 6-K | dp238568_6k.htm |
| 2025-12-08 | 6-K | dp238482_6k.htm |
| 2025-11-17 | 6-K | immatics_n.v._6-k_q325.htm |
| 2025-11-12 | 6-K | dp237236_6k.htm |
| 2025-10-27 | 6-K | dp236283_6k.htm |
| 2025-10-20 | 6-K | dp235990_6k.htm |